- Supported exchanges /
- PINK /
- USRM.PINK
US Stem Cell Inc (USRM PINK) stock market data APIs
U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.
US Stem Cell Inc Financial Data Overview
| 0.0001 | |
| 0.0001 | |
| - | |
| 0.0001 | |
| 0.0001 | |
| 0-0.0003 | |
| 64 151 | |
| 642 M | |
| 82 049 | |
| 0 | |
| -35.435 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
US Stem Cell Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 82 049
- EBITDA -1 870 923
- Earnings Per Share 0
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get US Stem Cell Inc Earnings via APIs
- Latest Release 2024-05-08
- EPS/Forecast 0
Get US Stem Cell Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
